Crinetics Initiates Phase 2/3 Pediatric Trial for CAH
Crinetics’ atumelnant has previously shown statistically significant 12‑week reductions in androstenedione and 17‑hydroxyprogesterone in Phase 2, and the company...
Pioneering Trial: 4D Path Advances Bladder Cancer Biomarkers
4D Path’s QPOR platform has been selected as an exploratory biomarker in the Phase II DAD-IO study (NCT04724018) in...
Aprea WEE1 Inhibitor Trial Shows Early Proof-of-Concept
A single patient with PPP2R1A-mutated uterine serous carcinoma achieved an unconfirmed partial response with a 50% reduction in target...
Breakthrough Study: Red-Light Therapy Offers Hope For Brains
In a randomized, season-long study of 26 NCAA Division I football players, active intranasal and transcranial photobiomodulation with a...
RevMed Doses First Patient in RAS(ON) G12V Inhibitor Trial
Revolution Medicines has dosed the first patient in RMC-5127-001 (NCT07349537), a first-in-human, open-label study of RMC-5127, a selective inhibitor...
Cortigent’s Orion System Shows Promising 6-Year Study Data
In a six-patient Early Feasibility Study with follow-up extending to six years, Cortigent’s Orion visual cortical prosthesis improved performance...
Kymera Announces First Patient Dosed in Asthma Drug Trial
Kymera has begun dosing in BREADTH, a global, randomized, double-blind, placebo-controlled Phase 2b study of KT-621 in approximately 264...
FDA Clears Scancell’s Phase 3 Trial for Advanced Melanoma
Updated Phase 2 data show a 74% progression-free survival rate at 16 months in the target population for iSCIB1+...
Longeveron Gets FDA Meeting for Pivotal HLHS Phase 2 Trial
Longeveron plans a third-quarter 2026 top-line readout for ELPIS II, a 40-patient, 12-site pivotal Phase 2b trial of laromestrocel...
LB Pharma Begins Phase 2 Trial for Bipolar Depression Drug
LB Pharmaceuticals has initiated ILLUMINATE-1, a U.S.-only, six-week, outpatient Phase 2 trial of LB-102 in bipolar I depression, randomizing...